Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 19;2(1):53-68.
doi: 10.20517/cdr.2018.25. eCollection 2019.

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

Gladys Olivera  1   2 , Luis Sendra  1   2 , María José Herrero  1   2 , Pablo Berlanga  3 , Pablo Gargallo  4 , Yania Yáñez  4 , Andrea Urtasun  4 , Jaime Font de Mora  5 , Victoria Castel  4 , Adela Cañete  4 , Salvador F Aliño  1   2
Affiliations
Review

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

Gladys Olivera et al. Cancer Drug Resist. .

Abstract

The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group). A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled.

Keywords: PharmGKB; Pharmacogenetic; Polymorphisms; clinical implementation; guidelines; oncology.

PubMed Disclaimer

Conflict of interest statement

All authors declared that there are no conflicts of interest.

References

    1. Ross CJD, Visscher H, Rod Rassekh S, Castro-Pastrana LI, Shereck E, et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol. 2011;18:134–51. - PubMed
    1. Conyers R, Devaraja S, Elliott D. Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. Pediatr Blood Cancer. 2018;65:e26937. doi: 10.1002/pbc.26937. - DOI - PubMed
    1. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–7. doi: 10.1038/clpt.2012.96. - DOI - PMC - PubMed
    1. Rodríguez AE, Herrero MJ, Bernal ML, Rojas L, Peiró AM. Personalized medicine into health national services: barriers and potentialities. Drug Metab Pers Ther. 2018 doi: 10.1515/dmpt-2018-0017. - DOI - PubMed
    1. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med. 2017;19:215–23. doi: 10.1038/gim.2016.87. - DOI - PMC - PubMed

LinkOut - more resources